This study was aimed to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa). A meta-analysis including 14 publications (15 cohorts) with 16,266 patients was performed to evaluate the association between NLR and overall survival (OS), progression-free survival (PFS)/recurrence-free survival (RFS) in PCa using hazard ratio (HR) and 95% confidence intervals (95% CI).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The combining data showed that increased NLR predict poor OS (HR = 1.38, 95%CI: 1.22-1.56) and PFS/RFS (HR = 1.24, 95%CI 1.05-1.46) in PCa. Stratified analysis by PCa type, sample size, ethnicity and NLR cut-off value revealed that NLR showed consistent prognostic value in metastatic castration-resistant prostate cancer (mCRPC) patients and predict poor PFS/RFS in Asians, but not in Caucasians. These statistical data suggested that increased NLR could predict poor prognosis in patients with PCa.
Scientific reports. 2016 Feb 25*** epublish ***
Xiaobin Gu, Xianshu Gao, Xiaoying Li, Xin Qi, Mingwei Ma, Shangbin Qin, Hao Yu, Shaoqian Sun, Dong Zhou, Wen Wang
Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China., Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.,